Johnson & Johnson (US) held the leading position in the biosurgery market in 2020. The company offers a wide range of biosurgery products including bone graft substitutes, soft tissue attachments, hemostats, staple line reinforcement agents, and surgical sealants and adhesives. The company has a strong geographic presence established through its manufacturing and distribution facilities, across the globe. The company leverages its research capabilities and innovative product portfolio to ensure a leading position in the biosurgery market. In FY2020, company invested about USD 12.2 Billion in R&D, out of which about USD 2.1 billion were invested in Medical Devices business segment, an increase of 9.8% in comparison to FY2019.
Medtronic Plc (Ireland) held the second position in the global biosurgery market. Company has exhaustive product portfolio, specifically in bone graft substitutes and soft tissue attachment category. Additionally, the company leverages its research capabilities and innovative product portfolio to ensure a leading position in the biosurgery market. In FY2020, the company invested USD 2,331 million in R&D, up from USD 2253 million in FY2018. Medtronic focuses on organic growth strategies such as innovation, product launch and approval for its growth in the biosurgery market, as evidenced by its recent product approval and launches during FY2018 to FY2019 across orthopedic and spine surgery portfolio.
The surgical sealants and adhesives segment is expected to grow at the highest CAGR
The orthopedic segment accounted for the largest share Hospitals segment accounted for the largest share Asia Pacific is expected to show the highest growth rate
